Ocaliva®

Active substance

obeticholic acid

Holder

Intercept Pharma Nederland BV

Status

Running

Indication

Treatment of patients with Primary Biliary cholangitis who completed the Long-Term Safety Extension of the POISE phase 3 trial (747-301 / EudraCT 2011-004728-36)

Public documents

Approbation

Information for the patient

Informed consent

Last update

05/08/2020

Last updated on 13/04/2021